CD8⁺ T cells, arising from thymic selection, are key components of the adaptive immune system (1,2). In the classical scenario, naïve CD8⁺ T cells encounter self or foreign antigens derived from tumors or invaded pathogens and undergo clonal expansion and functional maturation, giving rise to a heterogeneous effector population. These effector CD8⁺ T cells consist of cytotoxic T lymphocytes (CTLs) that form immune synapses with target cells to locally release perforins, granzymes and cytokines for focal killing. From the developmental perspective, three effector subpopulations with distinct fates are discerned: Short-lived effector cells [killer cell lectin-like receptor G1 (KLRG)⁺ CD127⁻), which are terminally differentiated and undergo apoptosis following the clearance of antigen; memory precursor effector cells (MPECs, KLRG⁻ CD127⁺), which develop into memory T cells; and rare long-lived effector cells (KLRG⁺ CD127⁺) which display the hybrid phenotype (3). Memory T cell subsets, including effector memory T cells that patrol peripheral circulation and non-lymphoid tissue, central memory T cells that recirculate through lymphoid organs due to the high expression of CCR7 and CD62L and tissue-resident memory T cells (TRMs) that have established stable tissue residency, are primarily derived from MPECs and constitute coordinated layers of CD8⁺ T cell-mediated immune response (3-5).

In a manner analogous to CD4⁺ helper T cells, effector CD8⁺ T cells can be polarized by specific cytokine milieus into context-dependent functional subsets, although such classification is not widely accepted due to lack of stable lineage-defining transcription factors and limited evidence for stable, heritable polarization of CD8⁺ T cells in vivo. Type 1 CD8⁺ T (Tc1) cells, defined by (T-box transcription factor expressed in T cells (T-bet) expression and IFN-γ production, are induced by IL-12 and type I IFN signaling to combat intracellular pathogens and tumors (6,7). Tc17 cells, characterized by retinoic acid-related orphan receptor γt (RORγt) expression and secretion of IL-17 and IL-22, differentiate in the presence of TGF-β and pro-inflammatory cytokines such as IL-6 or IL-21 to mediate mucosal immunity and autoimmune reactions (8,9). Tc22 cells, identified as IL-22 producers, are implicated in skin homeostasis and enriched in the tumor microenvironment (10,11). Regulatory CD8⁺ T cells (CD8⁺ Tregs), which suppress immune responses via cytolysis or IL-10, are typically induced by suboptimal antigen exposure under tolerogenic conditions (12,13). By contrast, antigen stimulation with insufficient costimulatory signals induces CD8⁺ T cell anergy (14), whereas chronic antigen exposure drives T cell exhaustion (15,16), establishing a hierarchy comprised of stem-like progenitor exhausted cells, their intermediate descendants that are still sensitive to immune checkpoint blockade, and the terminally exhausted population which has lost effector functions irreversibly (17,18).

With the advent of single-cell and muti-omic technologies, knowledge on CD8⁺ T cell plasticity has deepened. To meet the increasing demand of modern immunology on the functional heterogeneity of T cells, a modular nomenclature system is used to delineate their lineage, function, migratory capacity, differentiation state and antigen presence state (19). Moreover, progress has been made regarding the epigenetic, transcriptional and metabolic regulation of CD8⁺ T cell function (20). Understanding the molecular switches and signaling pathways essential for CD8⁺ T cell fate decision, effector competency and functional persistence is of key for translational purposes, such as manipulating CD8⁺ T cells for optimal anti-viral and anti-tumor response, or to circumvent the occurrence and decrease the intensity of autoinflammatory diseases. For example, by unraveling molecular machinery modulating the functionality, infiltration and robustness of chimeric antigen receptor (CAR)-T cells (21,22), the application of artificially engineered CD8⁺ T cells has been extended from blood malignancy to solid tumors and autoimmune disorders (21,23,24).

IFN regulatory factors (IRFs), known for their role in mediating IFN signaling and the transcription of IFN-stimulated genes (ISGs), serve a critical part in metabolic and immune regulation (25,26). IRFs contain a highly conserved N-terminus DNA-binding domain that recognizes IFN-stimulated response elements (5′-AAN NGA AA-3′) within the promoters of target genes (27), and the IRF-associated domain at the C-terminus (28). Based on the biological relevance, IRFs could be subdivided into several functional groups: IRF3/7/9 integrate various nucleic acid sensing pathways to facilitate the production of type 1 IFNs (29-31); IRF1 lies downstream of IFN stimulation along with its natural antagonist IRF2 (32); IRF4/5/8 respond to T/B cell receptor (CR) and cytokine stimulation (33-35). A recent study identified an intrinsic T lymphokine-activated killer cell-originated protein kinase (TOPK)-IRF5 axis in CD8⁺ T cells that suppresses antitumor immunity (36). IRF6 mutations cause Van der Woude syndrome, popliteal pterygium syndrome and non-syndromic orofacial cleft type 6 (37,38). Aberrant IRF signaling is associated with immune abnormalities (26,32), ranging from classical autoimmune diseases such as inflammatory bowel disease and type 1 diabetes to human autosomal dominant combined immunodeficiency (39,40), which stems from multimorphic IRF4 T95R mutation.

The roles of IRFs in dendritic cells (DCs), macrophages, B cells, CD4⁺ T cells and other immune cell types have been reported (35,41-43). Specifically, IRF1 serves a key role in both innate and adaptive immune responses through governing the expression of multiple anti-viral and immune-regulatory genes, thereby regulating cell proliferation, differentiation and apoptosis (44). By contrast, IRF2 serves as a natural antagonist of IRF1, suppressing the genes governed by IRF1 and working as a rheostat to safeguard immune homeostasis (45). IRF3 is activated upon recognition of pathogen-associated molecular patterns, especially double-stranded RNA, to initiate the production of type I IFNs (46), while IRF7 amplifies the IFN signal through an IFN feedback loop (47). Although in a traditional view, IRF8 is required for the development of type 1 conventional DC (cDC1) to activate CD8⁺ T cells (48) and IRF4 acts as a master transcription factor of CD4⁺ T cell-priming cDC2 (49), lung resident IRF4-dependent CD11b⁺ CD24^hi DCs are key for the formation of memory CD8⁺ T cells and TRMs during influenza A virus (IAV) infection (50). DC-specific IRF4 knockout (KO) mice demonstrate increased lung pathology upon challenge with heterosubtypic IAV, coupled with defective expansion of IFN-γ⁺ CD8⁺ T cells (50). Previous studies have reviewed the extrinsic regulatory effect of IRFs in cell types that exert an indirect impact on CD8⁺ T cells (51-53). The present review, however, aimed to summarize the intrinsic roles of IRFs in CD8⁺ T cell functional regulation.

The requirement for IRF1 in CD8⁺ T cell development is evidenced by the fact thatIRF1 deficient mice harbor a decreased number of mature CD8⁺ T cells in both thymus and peripheral lymphoid organs (54). Deficits in other lymphoid cells, including natural killer (NK) cells, NKT cells and intestinal intraepithelial lymphocytes (IELs), are also observed inIRF1 KO mice and the recovery of all these lymphocyte subsets could be accomplished through IL-15 administration (55,56). Reintroduction of BCL2 into thymocytes rescues the defect of CD8⁺ T cells, implying differential regulatory effects of IRF1 on distinct lymphocyte populations (57). The paucity of CD8⁺ T cells inIRF1 KO mice is partially ascribed to the capability of IRF1 to directly bind the promoter regions of transporter associated with antigen processing 1 (TAP1) and low molecular mass polypetide 2 (LMP2), the upregulation of which is central for the antigen presentation process and the development and maintenance of CD8⁺ T cells (58). However, another study argues that the CD8⁺ T cell-intrinsic effect of IRF1 rather than the extrinsic impact on the thymic microenvironment is responsible for impaired CD8⁺ T cell commitment inIRF1 KO mice (57). Despite decreased expression of TAP1, LMP2 and major histocompatibility complex (MHC)-I in IRF1 KO thymic stromal cells, they are capable of supporting CD8⁺ T cell development in vivo bone marrow transplantation and in vitro cell re-aggregation models (54,57). By contrast, TCR stimulation induces IRF1 expression in mature CD8⁺ T cells and IRF1 KO thymocytes demonstrate abrogated TCR signal transduction, thereby impairing both positive and negative selection processes (54). IRF1 is also key for the maintenance of memory-like T cell transcription factor 1 (TCF1)⁺ CD8⁺ T cells, which sustain T cell response in cancer and chronic infection by self-renewal and generating terminally differentiated T cells (59). Opposed to type 1 IFN signaling that couples the effector differentiation and cell division, IL-27 enhances the proliferative capacity of TCF1⁺ CD8⁺ T cells through the STAT1-IRF1 axis while impeding the terminal differentiation program (59).

The role of IRF1 in CD8⁺ T cell-mediated anti-infection response is an issue of debate. IRF1 deficiency inhibits CD8⁺ T cell proliferation, the production of IFN-γ and the surface expression of chemokine receptor CXCR3, which is key for the recruitment of CD8⁺ T cells into the brain, thereby ameliorating the immunopathological damage to the brain associated with malaria (60). In the case of inoculation of replication-defective adenovirus, IRF1 whole-body KO (Irf1^−/−) mice demonstrate initially reduced NK, CD8⁺ T, and NKT cell numbers in both spleen and liver, which recover over time (61). Although IRF1 is hypothesized to promote IFN-γ production in CD8⁺ T cells, adenovirus-afflicted IRF1^−/− mice show higher levels of IFN-γ and IL-18 and lower levels of myeloid-derived IL-12 (62). As a result, the temporary decrease in CD8⁺ T cells and the elevated expression of IFN-γ delay adenovirus eradication, pointing to the existence of compensatory mechanisms to support CD8⁺ T cell effector function under IRF1 deficiency (62). IRF1 ablation also brings about paradoxically diminished CD8⁺ T cells in naïve mice, yet a marked expansion of West Nile virus (WNV)-specific cytolytic CD8⁺ T cells upon infection to restrain the WNV spread (63). Therefore, the function of IRF1 in infectious disease might be heavily context-dependent, and more evidence is required to clarify this issue. Such context-dependence extends beyond infectious models. For example, in major depressive disorders, bioinformatic analyses reveal notable upregulation of the IRF1 transcriptional pathway within the peripheral immune cell transcriptome, suggesting its involvement in the sterile inflammatory response (57,64).

IRF2 is a natural antagonist of IRF1 (Fig. 1) (45,65-67). IRF1/IRF2 binding activity is weakly induced in MHC class I-restricted double-positive thymocytes but not in MHC class II-restricted models (57,68). IRF2 deficient mice exhibit decreased bone marrow hematopoiesis, B cell lymphopoiesis and high mortality rate following lymphocytic choriomeningitis virus (LCMV) infection, potentially due to the hyperactivation of proinflammatory CD8⁺ T cells (44). Mice lacking Irf2 develop spontaneous inflammatory skin disease with CD8⁺ T cells hyperresponsive to antigen stimulation and expressing IFN-stimulated genes (69), highlighting the repressive role of IRF2 in CD8⁺ T cell activation (70) and the homeostatic maintenance of the IFN system under physiological conditions (71). However, a unique function of IRF2 in IEL development is also reported. CD8αα⁺ IELs bearing TCRαβ or TCRγδ, but not CD8αβ⁺ IELs, are severely decreased in IRF2 deficient mice and the residual CD8αα⁺ TCRαβ⁺ IELs are functionally immature with low T-bet expression The requirement for IRF2 in IEL development is independent of IL-15, as the IRF2^−/− IL15^−/− double KO mice display more severe IEL defects than IL-15 single-deficient mice (72). Acute and transient IFN signaling may upregulate IRF1 to transcribe proinflammatory genes, while sustained IFN signaling in conditions such as tumor and chronic infection induces IRF2 upregulation to terminate IRF1 signaling and initiate immune suppressive programs. CD8⁺ T cell-specific deletion of IRF2 prevents T cell exhaustion and enables sustained effector functions that enhance responsiveness to immune checkpoint blockade and adoptive cell therapy (Fig. 1) (65,73,74).

Modulatory effects of IRF1 and IRF2 may be indirect. For example, IRF1 binds to the promoter region of Cxcl10 and enhances its expression in hepatocellular carcinoma, leading to the enhanced infiltration of CD8⁺ T cells within the tumor microenvironment, while the transcriptional activity of IRF1 is antagonized by IRF2 (75). In skin cutaneous melanoma, expression of IRF1 is controlled by four CpG sites (cg00255919, cg21138405, cg15375424 and cg27587780) within the Irf1 gene locus, and the expression of IRF1 is positively associated with the extent of CD8⁺ T infiltration in the tumor microenvironment (76). However, the association between IRF1 and CD8⁺ T cell states is reversed in autoimmune contexts. In systemic lupus erythematosus, IRF1 expression is downregulated in peripheral central memory CD8⁺ T cells during active disease, and its restoration is associated with remission, highlighting its dynamic and disease phase-specific role in immune homeostasis (77). IRF1 is also key for hepatic production of the IL-15/IL-15Rα complex, as Irf1 KO reduces the expression of IL-15 and IL-15Rα in hepatocytes, resulting in poor recruitment of NK, NKT and CD8⁺ T cells, and alleviates liver damage in the ischemia/reperfusion model (61).

IRF1 and IRF2 serve as opposing regulatory pairs to keep CD8⁺ T cell activation in check, reflected by the seemingly contradictory effects of IRF1/2 in anti-infection vs. anti-tumor responses. IRF1 upregulation or IRF2 ablation bolsters CD8⁺ T cell effector program but prevents CD8⁺ T cell exhaustion, offering therapeutic benefits in tumor eradication. However, compared with tumors, which are often hypo-immunogenic and immune evasive, virulent pathogens cause acute damage to the human body by inducing overactive immunopathological reactions that may be otherwise life-threatening in situations such as coronavirus disease 2019 infection (78). Meanwhile, chronic infection, such as those elicited by hepatitis B virus, induce CD8⁺ T cell exhaustion to allow pathogen persistence (79). Thus, IRF1/2 targeting strategies should be cautiously applied in infectious disease to balance the pathogen-killing and self-destructive effects of CD8⁺ T cells, based on understanding of specific pathogen type, the host immune status and the dynamic nature of host-pathogen interplay.

IRF3, IRF7 and IRF9 are critical IRF members involved in anti-viral response and the production of type 1 IFN through integrating diverse nucleic acid sensing pathways (30,80-83). Plasmacytoid DCs (pDCs) are the predominant producers of type 1 IFN, which promotes the proliferation of autoreactive CD8⁺ T cells and upregulates the expression of very late antigen-4/Lymphocyte function-associated antigen 1 (LFA1) on activated CD8⁺ T cells to facilitate their tissue infiltration (84). In skin, type 1 IFN is mainly produced by mononuclear phagocytes and is restrained by Tregs. Overproduction of type 1 IFN facilitates CD8⁺ T cell accumulation in the skin lesion, while type 1 IFN signaling blockade or CD8⁺ T cell depletion mitigates psoriasiform skin inflammation (85). In a murine model of lymphocytic choriomeningitis virus infection, type 1 IFN triggers the expression of inhibitory NK cell receptor ligands on T cells, protecting them from NK-mediated elimination and conferring prolonged anti-viral T cell immunity (86). In the diet-induced obesity model, upregulated IFNα in the liver causes the accumulation and activation of CD8⁺ T cells, associated with inflammation-associated insulin insensitivity and glucose dysregulation (87). IFNαR1^−/− and CD8⁺ T cell-specific IFNαR1^−/− chimeric mice and IFNαR1 inhibitors all suppress the type 1 IFN-CD8⁺ T cell axis, thereby improving the metabolic parameters of non-alcoholic fatty liver disease (87). Type 1 IFN is an antiproliferative cytokine hindering the expansion of CD8⁺ T cells, which inhibits the CD8⁺ T cell-mediated anti-infection response in vivo (88). The early presence of type 1 IFN (IFN-I) permits CD8⁺ T cell infiltration and activation; however, sustained IFN-I signaling impair CD8⁺ T cell function, and its decrease is therefore key for the expansion of full functional effector cells (Fig. 2) (89-91). This calibration of the type I IFN response is exemplified by its integration with cellular oxygen-sensing pathways. Environmental oxygen tension, sensed via the prolyl hydroxylase domain-containing protein 2-Hypoxia inducible factor 1-alpha (HIF1α) axis, directly modulates the activity of IRF3 and IRF7, thereby dictating the magnitude of IFN production and CD8⁺ T cell responses in a context-dependent manner (92).

Bovine viral diarrhea virus infection of bovine CD8⁺ T cells activates the PI3K-AKT signaling pathway to enhance the de novo lipid biosynthesis supporting viral replication. Inhibition of fatty acid synthase activates retinoid acid-inducible gene 1 and melanoma differentiation-associated protein 5, triggering the TANK binding kinase-IRF3 axis and the production of type 1 IFN (93). IRF3 deficient CD8⁺ T cells also manifest higher expression levels of IL-17A and IL-23 receptor, in the presence or absence of the stimulatory nucleic acid mimic polyinosinic–polycytidylic acid, the phenotype of which is further corroborated by adoptively transferring IRF3-KO OT-I CD8⁺ T cells. Mechanistically, via the IRF interaction domain, IRF3 interacts with cytoplasmic RORγt and prevents it from binding and transactivating the Il-17 promoter. Thus, IRF3 serves as a rheostat for the Tc17 program (94). Activation of the MyD88-IRF7 pathway in pDCs determines the production of type 1 IFN and induction of CD8⁺ T cell response (47). Additionally, the intrinsic regulatory effect of IRF7 is exemplified by microRNA (miR)-155, which is upregulated in effector and effector memory CD8⁺ T cells but downregulated in naïve and central memory CD8⁺ T cells. miR-155 deficient CD8⁺ T cells exhibit heightened type 1 IFN signaling and are more susceptible to the antiproliferative effect of IFN, which is rescued by inhibition of STAT1 or IRF7 (88). By contrast, IRF9 extrinsically prevents CD8⁺ T cell exhaustion in mice acutely infected with LCMV-Armstrong strain. IRF9 deficiency impairs the production of type 1 IFN from DCs, leading to unchecked LCMV replication and antigen exposure that causes CD8⁺ T cell exhaustion and chronic infection (95).

IRF8 indirectly impacts CD8⁺ T cell function in tumor development (96,97). In estrogen receptor-negative breast cancer, tumoral expression of IRF8 is positively associated with effector CD8⁺ T cell infiltration (98). IRF8 suppresses p53 expression to maintain the sensitivity of tumor cells to intrinsic ferroptosis triggered by tumor-reactive CTLs. IRF8-KO tumor cells acquire resistance to ferroptosis and grow faster in immune-competent mice. In patients with cancer, nivolumab (anti-PD-1 antibody) responders have higher IRF8 expression in their tumor cells as compared with non-responders, which implies IRF8 is a useful biomarker of cancer immunotherapy (99). IRF8 and IRF4 suppress the expression of inflammasome-associated genes in cDC1s and cDC2s, respectively, to prevent pyroptotic cell death and preserve their ability to prime both CD4⁺ and CD8⁺ T cells (100). IRF8 is key for the expansion of monocyte-derived tumor-associated macrophages (TAMs) and the activation of tumor cDC1s. While cDC1s prime CTLs in tumor-draining lymph nodes, TAMs enriched for IRF8 promote exhaustion of tumor-reactive CTLs and facilitate tumor growth (101), indicating a complex role of IRF8 in tumorigenesis.

Regarding the direct effect of IRF8 in CD8⁺ T cells, TCR/co-stimulation signals along with γc-cytokines converge on the upregulation of IRF8 to mediate the transition of naive CD8⁺ T cells into effector cells in graft vs. host disease mice, identifying IRF8 a key transcription factor in driving CD8⁺ T cell effector differentiation (34). Additionally, IRF8 serves as a potential intrinsic factor constraining effector to memory phenotype transition (102). Conditional ablation of IRF8 in T cells increases the frequency of virus-specific MPECs in herpes simplex virus 1 (HSV-1) induced eye infection, thereby promoting HSV-1-specific CD8⁺ T cell expansion and corneal inflammatory infiltration (102). These immunological changes facilitate the elimination of viruses residing within the trigeminal ganglion but risk ocular inflammation and limbitis (102). Thus, similarly to T-bet and emesodermin (Eomes), well-established drivers of the effector CD8⁺ T cell program (7,103,104), IRF8 is a hub transcription factor facilitating the same program (Fig. 3).

Alone or together with other partners, IRF family members serve as multifaceted transcription factors regulating CD8⁺ T cell biology. In common, nearly all IRFs pull CD8⁺ T cells away from the naïve state and favor the effector program by inducing Blimp1, T-bet or ID2. Nonetheless, combined and antagonistic actions exist between IRF members pertaining to the regulation of particular CD8⁺ T cell functional aspects. For thymic CD8⁺ T cell development and maturation, IRF1 is required due to its ability to stimulate TCR signaling and enhance the expression of antigen-presenting molecules (TAP1, LMP2, MHC-I) in thymic stromal cells. By contrast, IRF4 impedes CD8⁺ SP cell development by suppressing RUNX3 and IRF2 is critical for the generation of CD8⁺αα⁺ IELs. IRF1 promotes the expansion of memory-like CD8⁺ T cells. However, IRF8 hinders the transition from the effector state to the memory state and IRF4 impacts TRM maintenance. IRF4 facilitates the polarization of Tc17 while IRF3 restrains it by sequestering RORγt to prevent binding to the Il-17 promoter region. Finally, although type 1 IFN promotes CD8⁺ T cell survival and tissue infiltration, persistent stimulation of IFN may cause IRF7-mediated inhibition of CD8⁺ T cell expansion.

Despite the function of IRF4 in effector CD8⁺ T cell activation, its downregulation in CAR-T cells does not impair their cytotoxicity but instead achieves long-term persistence and better tumor control through the elevation of CD27 upon repetitive antigen encounter, contradicting the conventional hypothesis (144). Moreover, chronic and strong TCR stimulation drives the upregulation of IRF4, BATF and NFATc1, which together upregulate PD-1 and hinder memory T cell differentiation by suppressing TCF1 (33). These contradictory results suggest the complex and context-dependent roles of IRFs in regulating CD8⁺ T cell function. Although IRFs such as IRF4 increase glycolytic metabolism in CD8⁺ T cells and coordinate the epigenetic landscape in B cells (106,145), it is unknown whether extensive crosstalk exists between IRFs, metabolic rewiring and epigenetic remodeling in CD8⁺ T cell biology. Supporting the potential for such crosstalk, a multi-omics study in non-segmental vitiligo found increased chromatin accessibility at binding motifs for IRF1 and IRF4 in circulating CD8⁺ T cells and monocytes, which is associated with a pro-inflammatory gene expression signature (146).

IRFs, particularly their DNA-binding domains, are typically considered undruggable due to the flat and featureless surface, making it difficult to design small molecules that effectively inhibit their function (147). Despite this challenge, a recent study screened 210,000 compounds and identified two small molecules, IRF1-inhibitor-1 and -2, that effectively inhibit IRF1 transcriptional activity (148). In radiation-induced skin damage models, these inhibitors decrease IRF1 activation and alleviate skin damage (148,149). Imiquimod, widely applied in condyloma acuminate treatment, activates the TLR7-IRF7 pathway and has been increasingly explored in cancer immunotherapy (150,151). Imiquimod boosts antitumor response by enhancing CD8⁺ T cell effector function, particularly when combined with therapies such as PD-1/PD-L1 blockade (152).

To the best of our knowledge, no small molecules directly binding IRF4 and disrupting its DNA interaction have been reported in clinical trials. However, epigenetic modulation strategies show promise in indirectly suppressing the IRF4-MYC axis, a key pathway for multiple myeloma (MM) survival: Ishiguro et al (153) demonstrated that dual inhibition of the histone methyltransferases EZH2 and G9a suppresses MM cell proliferation by downregulating key genes, including IRF4 and MYC. Beyond direct DNA-binding inhibition, complementary strategies are emerging. Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 screens have identified synthetic lethal partners of IRF4, such as BATF, in certain types of B cell malignancy (154) and inhibitors disrupting IRF protein-protein interactions offer another avenue to modulate IRF activity (155). Advances in drug design platforms, including anti-sense oligonucleotides and targeted protein degradation constructs such as proteolysis-targeting chimeras (PROTACs) and lysosme-targeting chimeras (LYTACs), are expanding the toolbox for IRF-directed therapy beyond conventional small molecules. Notably, a first-in-class IRF4-selective PROTAC degrader has been shown to induce cytotoxicity in MM cells (156). By exploiting these platforms, novel IRF-targeting strategies may be developed. Nonetheless, given IRFs are widely expressed in various cell types (26,157), preclinical studies must evaluate the drug safety issue to minimize potential side effects of IRF inhibition. In this regard, future development should prioritize tissue- or cell-specific targeting strategies that restrict IRF modulation to disease-relevant cells or local microenvironments, thereby circumventing off-target effects and improving therapeutic windows.

In summary, while pharmacological targeting of IRFs presents challenges, strategies are emerging to modulate their activities. The observation that virus-specific CD8⁺ T cell memory can persist for a decade prompts the question of whether specific IRF-driven transcriptional programs underpin durable immunity (158). As research bridges these mechanistic insights with therapeutic innovation, the IRF family is positioned at the forefront of immunology and translational medicine.